What did Pacific Edge (ASX:PEB) announce regarding its capital raising?

Pacific Edge finalised a NZ$36.1 million capital raising campaign following the closure of its heavily oversubscribed retail offer. The capital raising originally targeted NZ$31.4 million on 13 May, combining a NZ$25.4 million institutional placement and a NZ$6 million retail offer.

How much demand did the Pacific Edge (ASX:PEB) retail offer receive?

The retail offer received NZ$46 million in total applications by its closing date on 28 May, far exceeding the initial NZ$6 million target. In response to this strong demand, the company's directors exercised their discretion to accept NZ$4.7 million in oversubscriptions.

At what price were the new Pacific Edge (ASX:PEB) shares issued?

The new ordinary shares issued under the capital raising were priced at NZ$0.17 per share. This fixed price applied to both the institutional placement and the subsequent retail offer. Under the retail segment alone, Pacific Edge will issue a total of 62,703,746 new ordinary shares at this valuation.

How is the retail portion of the Pacific Edge (ASX:PEB) capital raising structured?

Out of the NZ$10.7 million raised in the retail offer, NZ$10.2 million is structured under standard share purchase plan rules. The remaining NZ$0.5 million utilises the company’s existing placement capacity under listing rules. This dual structure allowed Pacific Edge to legally accommodate the extra NZ$4.7 million in oversubscriptions from retail traders.

Image for illustrative purposes only. Not a real photo.

Pacific Edge finalises NZ$36.1M capital raising

Q: What does this capital raising mean for existing Pacific Edge (ASX:PEB) retail shareholders?

The expansion of the retail offer to NZ$10.7 million allowed the vast majority of eligible retail applicants to retain their relative pre-capital raising shareholdings. This means participating retail investors faced less dilution than they would have under the original NZ$6 million cap.

Written by Liezl GambePublished Jun 2, 2026, 11:01 PM

Cancer diagnostics company Pacific Edge (ASX:PEB) has finalised a NZ$36.1 million capital raising campaign after its retail offer closed oversubscribed.

The Dunedin-based firm initially confirmed a NZ$31.4 million capital raising on May 13, which featured a NZ$25.4 million institutional placement and a NZ$6 million retail offer priced at NZ$0.17 per share.

Following overwhelming demand that generated NZ$46 million in total applications by the 28 May closing date, company directors exercised their discretion to accept NZ$4.7 million in oversubscriptions.

The expansion lifted the total retail offer capital to NZ$10.7 million, ensuring the vast majority of eligible retail applicants retained their relative pre-capital raising shareholdings.

Under this retail segment, 62,703,746 new ordinary shares will be issued, with NZ$10.2 million structured under share purchase plan rules and the remaining NZ$0.5 million utilising the company’s placement capacity.

Pacific Edge confirmed that the allotment, confirmation despatch, and NZX trading commencement for these new shares are scheduled for June 4, while any surplus application refunds will be processed within five business days of settlement.

Chairman Simon Flood stated that the capital injection places Pacific Edge in a strong strategic position.

He emphasised that the long-term global opportunities for the company’s flagship Cxbladder diagnostic product have been reinforced by the quality of its clinical evidence and the support shown by both existing institutional and retail shareholders.